Anlotinib Inhibits Tumor Angiogenesis and Promotes the Anticancer Effect of Radiotherapy on Esophageal Cancer through Inhibiting EphA2

BACKGROUND: Anlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis and has antitumor activity in a variety of solid tumors. Given that, our study was designed to unearth the mechanism of anlotinib in radioresistant esophageal cancer (EC) cells. METHODS: Radioresistant EC c...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Zhenlin, Zhu, Weiguo, Wang, Wanwei, Xu, Yingying, Jiang, Lei, Huang, Jiasheng, Huang, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452983/
https://www.ncbi.nlm.nih.gov/pubmed/36090890
http://dx.doi.org/10.1155/2022/5632744

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452983/
https://www.ncbi.nlm.nih.gov/pubmed/36090890
http://dx.doi.org/10.1155/2022/5632744

Ejemplares similares